Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
-
2121
-
2122
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2123
-
2124
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2125
-
2126
-
2127
-
2128
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2129
-
2130
-
2131
-
2132
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2133
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2134
-
2135
-
2136
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2137
-
2138
-
2139
-
2140